TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03475953
Drug: Phase 2 : Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
Study: NCT03475953
Drug: Phase 2 : Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
Study: NCT03475953
Drug: Phase 2: low-dose Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
Study: NCT02259075
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00953459
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01752712
Drug: CBSST + Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Study: NCT02969733
Drug: Xylocaine
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
Study: NCT02969733
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
Study: NCT04958512
Drug: Hydergotoxine mesylate tablets
Normalized name: dihydroergotoxine
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
Study: NCT00552227
Drug: ruboxistaurin
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 32 mg daily
Study: NCT00069160
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
Study: NCT00069160
Drug: tariquidar
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
Study: NCT01566669
Drug: Parecoxib Sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Study: NCT03091894
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
Study: NCT03091894
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
Study: NCT00736931
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam 10 mg tablets
Study: NCT00736931
Drug: levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg tablets
Study: NCT00736931
Drug: lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lorazepam 2 mg over encapsulated tablets
Study: NCT03110315
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See detailed information in associated Arm Description.
Study: NCT01781468
Drug: armodafinil 150 mg
Normalized name: armodafinil 150 MG
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orally
Study: NCT01781468
Drug: armodafinil 250 mg
Normalized name: armodafinil 250 MG
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orally
Study: NCT03365609
Drug: bismuth quadruple therapy
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
Study: NCT01396278
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate HFA MDI
Study: NCT02462382
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
Study: NCT01396278
Drug: BI 54903
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 54903 via Respimat inhaler
Study: NCT02462382
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
Study: NCT02966522
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02966522
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04470622
Drug: Aprepitant injectable emulsion
Normalized name: aprepitant Injection
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant injectable emulsion, once daily (QD) for 14 days.
Study: NCT03519022
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
Study: NCT03519022
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study: NCT02337829
Drug: Acalabrutinib (Arm A)
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z
Study: NCT02337829
Drug: Acalabrutinib (Arm B)
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.
Study: NCT01255579
Drug: Salmeterol Fluticasone
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
Study: NCT01255579
Drug: formoterol - beclometasone
Normalized name: formoterol and beclometasone
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
Study: NCT02913508
Drug: Vedolizumab intravenous injection
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous injection
Study: NCT02913508
Drug: Vedolizumab subcutaneous injection
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab subcutaneous injection
Study: NCT00999804
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg of Lapatinib by mouth daily
Study: NCT00999804
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
Study: NCT00999804
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg intravenously, every 3 weeks
Study: NCT03675815
Drug: Darunavir (DRV) 800 milligram (MG) Oral Tablet
Normalized name: darunavir 800 MG
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800 milligrams (mg) orally once daily for 96 weeks
Study: NCT03675815
Drug: Ritonavir 100 MG Oral Tablet
Normalized name: RITONAVIR 100 mg ORAL TABLET
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg orally once daily for 96 weeks
Study: NCT03675815
Drug: N(t)RTIs
Normalized name: nystatin / triamcinolone acetonide Topical Ointment [N.T.A.]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
Study: NCT03675815
Drug: Dolutegravir 50 MG Oral Tablet
Normalized name: dolutegravir 50 MG Oral Tablet
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg orally once daily for 96 weeks
Study: NCT03675815
Drug: FTC 200 MG Oral Cap
Normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
Study: NCT03127800
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
Study: NCT06379360
Drug: Hypomethylating agent, Azacitidine or Decitabine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
Study: NCT00375869
Drug: Darbeopoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Study: NCT00375869
Drug: Normal Saline (Placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Study: NCT03609593
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
Study: NCT03609593
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration.
Study: NCT03609593
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
Study: NCT01496690
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
Study: NCT01496690
Drug: Pregabalin Placebo Capsules
Normalized name: pregabalin Oral Capsule
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parallel to Active Comparator
Study: NCT02739802
Drug: Coppertone(BAY987517)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
Study: NCT00464256
Drug: rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03948737
Drug: Alpha-Tocopherol
Normalized name: Alpha-tocopherol
DrugBank: alpha-Tocopherol succinate (DB14001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
Study: NCT00822861
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL, 1 mg BID for 4 days
Study: NCT00822861
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL, 2 mg BID for 4 days
Study: NCT00822861
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL, 4 mg BID for 4 days
Study: NCT00822861
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL, 8 mg OD for 4 days
Study: NCT00268554
Drug: dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00079144
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02775227
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01142089
Drug: Rifamycin SV MMX
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
Study: NCT00910247
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 to 2400 mg once daily (QD)
Study: NCT01954147
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 therapy
Study: NCT02020720
Drug: Fluorine F 18 Fluorodopa
Normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo 18F-DOPA-PET/CT
Study: NCT00320723
Drug: bupropion, transdermal nicotine patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02086279
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured.
Study: NCT01757691
Drug: Fingolimod 0.5mg/daily
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02075840
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT02075840
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT04518202
Drug: lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
Study: NCT04518202
Drug: Sham patch
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
Study: NCT03762538
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be induced to unconsciousness using propofol intravenously.
Study: NCT02346578
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02346578
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01554631
Drug: Acarbose (Glucobay ODT, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01554631
Drug: Acarbose (Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039871
Drug: REBETOL (ribavirin; SCH 18908)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
Study: NCT01966692
Drug: Fluticasone Propionate Formulation 1
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate dry powder inhaler Formulation 1
Study: NCT01966692
Drug: Fluticasone Propionate Formulation 2
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate dry powder inhaler Formulation 2
Study: NCT01966692
Drug: Fluticasone Propionate Formulation 3
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate dry powder inhaler Formulation 3
Study: NCT03382977
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Study: NCT03382977
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Study: NCT03699319
Drug: CPI 613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months
Study: NCT00727233
Drug: Nexavar (BAY 43-9006) (Sorafenib)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03699319
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study: NCT03699319
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study: NCT03699319
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)